Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Watson

- PMLiVE

Pfizer’s Bosulif gets conditional green light for CML in Europe

Follows US approval last year

- PMLiVE

NICE: Pfizer’s lung cancer drug Xalkori too expensive for NHS

Pharma company says NICE's data demands need to take ethics into account

inVentiv invests in virtual trials

Acquires equity stake in US-based Mytrus

- PMLiVE

Former Pfizer R&D head LaMattina to advise Ziarco

He previously spent 30 years at US pharma firm

- PMLiVE

Former Pfizer VP James Taylor joins INC Research

He was previously VP global clinical trial management at the US pharma firm

- PMLiVE

Pfizer drops hepatitis C candidate filibuvir

Compound was lagging behind investigational drugs from Gilead and AbbVie

- PMLiVE

Pfizer sues as Celebrex patent is reissued in US

Court extends exclusivity of osteoarthritis treatment by 18 months

- PMLiVE

NICE recommends BMS-Pfizer’s Eliquis to prevent stroke

Joins Xarelto and Pradaxa anticoagulants as potential warfarin replacement

- PMLiVE

Actavis sales rise but profits slump as Lipitor effect recedes

Reports first set of results since merger with Watson

- PMLiVE

Channel strategy in pharma

Channel strategy could be a significant 'stone unturned' in the battle to win customers and patients

Teva facing $2bn liability for at-risk generic Protonix launch

Potential litigation costs from Pfizer are triple the generics firm's original estimates

- PMLiVE

Building brand strength – Part 4

Commitment, responsiveness and protection – how far will Big Pharma go to preserve its brands?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links